Business
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
PRESS RELEASE MASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS, INCLUDING MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS AND ALZHEIMER'S DISEASE Paris, May 15, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced publication of research in the pee
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"MASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL ","length":103,"tagName":"p"},{"type":"text","content":"A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS, INCLUDING MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS AND ALZHEIMER'S DISEASE","length":261,"tagName":"p"},{"type":"text","content":"Paris, May 15, 2025, 8am CET","length":28,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced publication of research in the peer-reviewed scientific journal PLOS One [1], highlighting the neuroprotective potential of masitinib in a model of neuroimmune-driven neurodegenerative disease. This research demonstrates masitinib’s ability to limit neuronal damage, as measured by serum neurofilament light chain (NfL) concentration, and reduce pro-inflammatory cytokine biomarkers, offering hope for its application in treating neurodegenerative diseases.","length":518,"tagName":"p"},{"type":"text","content":"NfL is a non-specific marker of axonal loss that can serve as a biomarker of a drug’s ability to produce a neuroprotective effect. Importantly, neuronal damage, or prevention thereof, can be rapidly assessed by measuring serum NfL concentration in EAE-induced mice. Because EAE is a model of neuroimmune-driven neurodegenerative disease, it is highly relevant to masitinib's mechanism of action in diseases such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson’s disease.","length":541,"tagName":"p"},{"type":"text","content":"The article, entitled ‘Tyrosine kinase inhibitor, masitinib...